Description
Dapagliflozin 10 mg, Sitagliptin 100 mg & Metformin Hydrochloride (ER) 1000 mg is a triple fixed-dose combination (FDC) tablet used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The three active agents work through complementary mechanisms to target different aspects of hyperglycemia.
Mechanism of Action:
Dapagliflozin (SGLT2 Inhibitor)
- Blocks sodium-glucose co-transporter 2 in the proximal renal tubules
- Reduces glucose reabsorption in the kidneys
- Increases urinary glucose excretion → lowers blood glucose levels
- Provides additional benefits: weight loss and blood pressure reduction
Sitagliptin (DPP-4 Inhibitor)
- Inhibits DPP-4 enzyme → increases GLP-1 and GIP incretin levels
- Enhances glucose-dependent insulin secretion and suppresses glucagon
- Improves postprandial and fasting glucose control
Metformin (ER – Biguanide)
- Decreases hepatic glucose production (gluconeogenesis)
- Improves insulin sensitivity
- Decreases intestinal glucose absorption
- Lowers fasting plasma glucose with low hypoglycemia risk
Indications:
Adults with type 2 diabetes mellitus as:
- Initial therapy in patients with markedly elevated blood glucose
- Step-up therapy when monotherapy or dual therapy is insufficient
- Substitution therapy in patients already stabilized on the individual components
-
